Observe Medical ASA: Receipt of subscription rights in the rights issue by primary insiders and close associates
Observe Medical ASA (OBSRV) · publisert 2023-11-27 18:00 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Soleglad Invest AS nærstående | Closely associated person of primary insider Kathrine Gamborg Andreassen (board member) | subscription | 2 320 037 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 2 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Ingerø Reiten Investment Company AS nærstående | Closely associated person of primary insider Terje Bakken (chairman of the board) | subscription | 38 176 442 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 3 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Navamedic ASA nærstående | Closely associated person of primary insider Terje Bakken (chairman of the board) | subscription | 16 699 196 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 4 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Athend Holding AS nærstående | Closely associated person of primary insider Eskild Endrerud (board member) | subscription | 15 794 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 5 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| ELI AS nærstående | Closely associated person of primary insider Eskild Endrerud (board member) | subscription | 6 897 850 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 6 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Seed Capital AS nærstående | Closely associated person of primary insider Eskild Endrerud (board member) | subscription | 253 359 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 7 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Per Arne Nygård | Chief Financial Officer (CFO) in Observe Medical ASA | subscription | 865 744 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 8 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| Rune Christian Nystad | Chief Executive Officer (CEO) in Observe Medical ASA | subscription | 154 992 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue / 9 NOTIFICATION BY PRIMARY INSIDERS/ CLOSE ASSOCIATE | rules · til gjennomgang |
| US Holding AS | Closely associate person of primary insider Rune Christian Nystad (CEO) | subscription | 525 590 | 0 NOK | 2023-11-27 | NO0013076943 | Outside a trading venue | rules · til gjennomgang |
Vedlegg
- Observe_Medical_ASA_Receipt_of_subscription_rights_in_the_rights_issue_by_primary_insiders_and_close_associates.pdf (tekst hentet ut)
- Observe_Medical_ASA_Notification_by_Primary_Insiders_and_Close_Associate.pdf (tekst hentet ut)
Meldingstekst
Reference is made to the stock exchange announcement published by Observe
Medical ASA (the "Company") on 22 November 2023, regarding the extraordinary
general meeting's approval of the contemplated rights issue raising gross
proceeds of up to NOK 55 million (the "Rights Issue"). Reference is further made
to the stock exchange announcement published on 24 November 2023 regarding the
approval by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet)
of the prospectus prepared by the Company for the offer and listing on the Oslo
Stock Exchange (Euronext Expand) of up to 211,538,461 Offer Shares in the Rights
Issue.
The subscription period in the Rights Issue will commence on 28 November 2023 at
09:00 hours (CET). As part of this process, subscription rights in the Rights
Issue have been allocated to primary insiders and their close associates.
Please see the attached mandatory notifications of trade for information
regarding the primary insiders' and their close associates' receipt of
subscription rights in the Rights Issue.
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.